Edmund Harrigan - Net Worth and Insider Trading

Edmund Harrigan Net Worth

The estimated net worth of Edmund Harrigan is at least $18 Million dollars as of 2024-07-25. Edmund Harrigan is the Director of Karuna Therapeutics Inc and owns about 55,163 shares of Karuna Therapeutics Inc (KRTX) stock worth over $18 Million. Edmund Harrigan is the Director of ACADIA Pharmaceuticals Inc and owns about 1,000 shares of ACADIA Pharmaceuticals Inc (ACAD) stock worth over $18,480. Edmund Harrigan is also the Director of PhaseBio Pharmaceuticals Inc and owns about 6,000 shares of PhaseBio Pharmaceuticals Inc (PHASQ) stock worth over $1. Details can be seen in Edmund Harrigan's Latest Holdings Summary section.

Disclaimer: The insider information is derived from SEC filings. The estimated net worth is based on the assumption that Edmund Harrigan has not made any transactions after 2020-12-03 and currently still holds the listed stock(s).

GuruFocus Premium Membership
30 Years of Financial Data on One Screen
Unlimited Filters in All-in-One Stock Screener
Exclusive Earnings Calls & Stock Analysis
Customizable Stock Dashboard
Real-Time Insider Trading Alerts
8,000+ Institutional Investors’ 13F Holdings
Excel & Google Sheets Integration
Downloadable Data
Quick Customer Support
And Much More...

Transaction Summary of Edmund Harrigan

To

Edmund Harrigan Insider Ownership Reports

Based on ownership reports from SEC filings, as the reporting owner, Edmund Harrigan owns 5 companies in total, including Incyte Corp (INCY) , Karuna Therapeutics Inc (KRTX) , and ACADIA Pharmaceuticals Inc (ACAD) among others .

Click here to see the complete history of Edmund Harrigan’s form 4 insider trades.

Insider Ownership Summary of Edmund Harrigan

Ticker Comapny Transaction Date Type of Owner
INCY Incyte Corp 2023-09-29 director
KRTX Karuna Therapeutics Inc 2020-08-12 director
ACAD ACADIA Pharmaceuticals Inc 2019-06-26 director
LIMIT LIMIT 2020-12-03 director
LIMIT LIMIT 2018-02-20 director

Edmund Harrigan Latest Holdings Summary

Edmund Harrigan currently owns a total of 3 stocks. Among these stocks, Edmund Harrigan owns 55,163 shares of Karuna Therapeutics Inc (KRTX) as of August 12, 2020, with a value of $18 Million and a weighting of 99.9%. Edmund Harrigan owns 1,000 shares of ACADIA Pharmaceuticals Inc (ACAD) as of August 16, 2016, with a value of $18,480 and a weighting of 0.1%. Edmund Harrigan also owns 6,000 shares of PhaseBio Pharmaceuticals Inc (PHASQ) as of December 3, 2020, with a value of $1 and a weighting of 0%.

Latest Holdings of Edmund Harrigan

Ticker Comapny Latest Transaction Date Shares Owned Current Price ($) Current Value ($)
KRTX Karuna Therapeutics Inc 2020-08-12 55,163 329.83 18,194,412
ACAD ACADIA Pharmaceuticals Inc 2016-08-16 1,000 18.48 18,480
PHASQ PhaseBio Pharmaceuticals Inc 2020-12-03 6,000 0.00 1

Holding Weightings of Edmund Harrigan


Edmund Harrigan Form 4 Trading Tracker

According to the SEC Form 4 filings, Edmund Harrigan has made a total of 3 transactions in Karuna Therapeutics Inc (KRTX) over the past 5 years, including 0 buys and 3 sells. The most-recent trade in Karuna Therapeutics Inc is the sale of 10,000 shares on August 12, 2020, which brought Edmund Harrigan around $833,200.

According to the SEC Form 4 filings, Edmund Harrigan has made a total of 0 transactions in ACADIA Pharmaceuticals Inc (ACAD) over the past 5 years. The most-recent trade in ACADIA Pharmaceuticals Inc is the acquisition of 1,000 shares on August 16, 2016, which cost Edmund Harrigan around $32,970.

According to the SEC Form 4 filings, Edmund Harrigan has made a total of 1 transactions in PhaseBio Pharmaceuticals Inc (PHASQ) over the past 5 years, including 1 buys and 0 sells. The most-recent trade in PhaseBio Pharmaceuticals Inc is the acquisition of 6,000 shares on December 3, 2020, which cost Edmund Harrigan around $24,720.

Insider Trading History of Edmund Harrigan

No transactions are available. GuruFocus only tracks and displays the purchase and sale of non-derivative security in open market or private transactions from SEC filings with the transaction code of P or S.
Total 0
  • 1
Only the transactions in Open Market or Private Sale at the market prices are included. Other transactions such as conversion of derivative security or exercise of options are not included. Insiders are limited to only officers and/or directors of the company.

Edmund Harrigan Trading Performance

GuruFocus tracks the stock performance after each of Edmund Harrigan's buying transactions within different timeframes. To be detailed, the average return of stocks after 3 months bought by Edmund Harrigan is -10.06%. GuruFocus also compares Edmund Harrigan's trading performance to market benchmark return within the same time period. The performance of stocks bought by Edmund Harrigan within 3 months outperforms 0 times out of 2 transactions in total compared to the return of S&P 500 within the same period.

You can select different timeframes to see how Edmund Harrigan's insider trading performs compared to the benchmark.

Please note GuruFocus will not track the insiders’ transaction performance if he/she does not have buying transactions.

Performance of Edmund Harrigan

Average Return

LIMIT
Average return per transaction

Outperforming Transactions

LIMIT
0 out of 2 outperforming transactions.
Each transaction is measured over a period and compared to .
1 Month 3 Months 6 Months 1 Year 2 Years 3 Years
Return(%) -6.18 LIMIT LIMIT LIMIT LIMIT LIMIT
Relative Return to S&P 500(%) -6.5 LIMIT LIMIT LIMIT LIMIT LIMIT

Edmund Harrigan Ownership Network

Ownership Network List of Edmund Harrigan

No Data

Ownership Network Relation of Edmund Harrigan

Insider Network Chart

Edmund Harrigan Owned Company Details

What does Incyte Corp do?

Who are the key executives at Incyte Corp?

Edmund Harrigan is the director of Incyte Corp. Other key executives at Incyte Corp include See Remarks Barry P Flannelly , Principal Accounting Officer Thomas Tray , and EVP & Chief Medical Officer Steven H Stein .

Incyte Corp (INCY) Insider Trades Summary

Over the past 18 months, Edmund Harrigan made no insider transaction in Incyte Corp (INCY). Other recent insider transactions involving Incyte Corp (INCY) include a net sale of 28,618 shares made by Barry P Flannelly , a net sale of 28,876 shares made by Steven H Stein , and a net sale of 7,657 shares made by Vijay K Iyengar .

In summary, during the past 3 months, insiders sold 29,711 shares of Incyte Corp (INCY) in total and bought 0 shares, with a net sale of 29,711 shares. During the past 18 months, 138,413 shares of Incyte Corp (INCY) were sold and 0 shares were bought by its insiders, resulting in a net sale of 138,413 shares.

Incyte Corp (INCY)'s detailed insider trading history can be found in Insider Trading Tracker table.

To

Incyte Corp Insider Transactions

No Available Data

Edmund Harrigan Mailing Address

Above is the net worth, insider trading, and ownership report for Edmund Harrigan. You might contact Edmund Harrigan via mailing address: C/o Acadia Pharmaceuticals Inc., 12830 El Camino Real, Suite 400, San Diego Ca 92130.

Discussions on Edmund Harrigan

No discussions yet.